Inkyu K Kim - Influenza Division, Centers for Disease Control and Prevention Battelle Memorial Institute

基本信息

浏览量：5

职业迁徙

个人简介

Health Economic Outcomes Research: statistical models, evidence synthesis, surrogacy modeling, and health economics modeling for Immuno-oncology therapy

研究兴趣

论文共 30 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

An Evaluation of an Algorithm for the Selection of Flexible Survival Models for Cancer Immunotherapies: Pass or Fail

Nicholas R. Latimer,Kurt Taylor,Anthony J. Hatswell, Sophia Ho, Gabriel Okorogheye,Clara Chen,Inkyu Kim,John Borrill,David Bertwistle

PharmacoEconomicspp.1-18, (2024)

引用0浏览0WOS引用

Treatment Effect Waning in Immuno-oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence with Proposals to Guide Modelling

Kurt Taylor,Nicholas R. Latimer, Thomas Douglas,Anthony J. Hatswell, Sophia Ho,Gabriel Okorogheye,John Borril,Clara Chen,Inkyu Kim,David Bertwistle

PharmacoEconomicsno. 11 (2024): 1181-1196

引用0浏览0WOS引用

A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France

Paul Casabianca,Marc Massetti,François-Emery Cotte, Romain Moreau,Sarah Kassahun,Prianka Singh,Inkyu Kim, Anne-Françoise Gaudin, Guillaume Piessen,Henri Leleu

PHARMACOECONOMICS-OPEN（2024）

引用0浏览0WOS引用

Correlation Between Pathologic Complete Response, Event-Free Survival/disease-Free Survival and Overall Survival in Neoadjuvant And/or Adjuvant HR+/HER2-breast Cancer

Anagha Gogate,Sandip Ranjan, Amit Kumar,Hitesh Bhandari,Eros Papademetriou,Inkyu Kim,Ravi Potluri

FRONTIERS IN ONCOLOGY (2023)

引用1浏览0引用

An Indirect Assessment of Individual-Level Association Between Disease-Free Survival (DFS) and Overall Survival (OS) for Resectable Esophageal or Gastroesophageal Junction Cancer (EC/GEJC): A Pooled Analysis of Randomized Controlled Trials (rcts) by an Illness-Death Model

Oguzhan Alagoz,Jaffer A. Ajani, Swetha Srinivasan,Inkyu Kim,Prianka Singh,Murat Kurt

Journal of clinical oncologyno. 4_suppl (2023): 369-369

引用0浏览0引用

Disease-free survival (DFS) as a surrogate endpoint (SE) for overall survival (OS) in early-stage resected esophageal/gastroesophageal junction cancer (EC/GEJC): An analysis of SEER-Medicare data

Jaffer A. Ajani,Lisa Leung,Steve Kanters,Prianka Singh,Murat Kurt,Inkyu Kim,Mir-Masoud Pourrahmat,Howard S. Friedman,Prakash Navaratnam,Gregory Reardon

Journal of Clinical Oncologyno. 4_suppl (2023): 321-321

引用0浏览0引用

Abstract P2-12-09: Correlation Between Pathologic Complete Response (pcr), Event-Free Survival (Efs)/disease-Free Survival (DFS) and Overall Survival (OS) in Neoadjuvant And/or Adjuvant (nadj/adj) Hormone Receptor Positive (HR+) and Human Epidermal Growth Factor Receptor-2 Negative (HER2-) Breast Cancer (BC)

Anagha Gogate,Inkyu Kim,Sandip Ranjan, Amit Kumar,Eros Papademetriou,Hitesh Bhandari,Ravi Potluri

Cancer researchno. 4_Supplement (2022): P2-09

引用0浏览0引用

1218P Long-term Survivorship Rates among Chemotherapy Refractory or Intolerant Advanced Esophageal Squamous Cell Carcinoma (aescc) Patients Treated with Nivolumab (NIVO)

J. A. Ajani,D. J. Sharpe,T. De,I. Kim, J. A. Gricar,M. Kurt

ANNALS OF ONCOLOGY（2022）

引用0浏览0引用

POSB276 Network Meta-Analyses of Nivolumab Plus Fluoropyrimidine and Platinum Chemotherapy Versus Recommended Treatment Regimens in 1L Gastroesophageal Adenocarcinoma

M. Grevinga,W. Bouwmeester,J. A. Spoorendonk, H. Xiao,I Kim,D. Bertwistle

VALUE IN HEALTH（2022）

引用0浏览0引用

MSR12 Eliciting Unreported Subgroup-Specific Survival in Randomized Controlled Trials (RCTS): A Non-Parametric Linear Optimization Approach

O. Alagoz,S. Srinivasan, H. Xiao,P. Singh,J. Gricar,M. Dixon,I Kim,M. Kurt

Value in health（2022）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn